HealthEquity (HQY) announced its initial outlook for its fiscal year ending January 31, 2027 and reaffirmed previously provided guidance for its fiscal year ending January 31, 2026. For the fiscal year ending January 31, 2027, management expects revenues in the range of $1.38B-$1.41B with Adjusted EBITDA margin of 43.8% to 44.3% and a yield on HSA Cash of approximately 3.75%. “Today, we issued our initial fiscal 2027 outlook, reflecting the progress we’ve made strengthening HealthEquity’s foundation and building momentum as a scaled platform,” said Scott Cutler, President and CEO of HealthEquity. “Over the past year, we’ve modernized the business, raising the bar on security and trust, accelerating the digital experience, and driving engagement, so the model compounds over time. Healthcare affordability is a structural challenge, making HSAs increasingly central to how Americans finance care. With our scale and an ecosystem of 200+ integrated Network Partners, including health and retirement plan partners, brokers and benefit advisors, we believe HealthEquity is positioned to drive durable growth and create long-term value for shareholders.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HQY:
- HealthEquity downgraded to Sell from Neutral at Goldman Sachs
- HealthEquity price target raised to $125 from $120 at KeyBanc
- HealthEquity initiated with an Overweight at Barclays
- HealthEquity Inc. Reports Strong Q3 Earnings and Growth
- HealthEquity price target raised to $120 from $117 at Deutsche Bank
